Companies ›Healthcare ›1099.HK

1099.HK — HKEX Pharmaceuticals

Sinopharm Group Co Ltd

HK$17,43

Open in Charts → Attach watcher ⌖

— —

HKD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

4,25 %

Op margin

2,7 %

ROE

8,5 %

Net margin

1,2 %

Debt / equity

0,85

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Sinopharm Group Co Ltd is a Chinese pharmaceutical company that operates in the healthcare sector, primarily generating revenue through the production and distribution of pharmaceutical products.

Business. Sinopharm Group Co Ltd (1099.HK) is a healthcare company operating in the pharmaceuticals and medical research industry. The firm generates revenue through the sale of pharmaceutical products. It is headquartered in China and is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

ActivityPharmaceuticals & Medical Research

Generated · model-assisted

Sell-side consensus

BUY17 analysts

11 buy6 hold0 sell

Avg 12m price target22,61

Analyst recommendations

17 analysts · consensus Buy

Buy11

Hold6

Sell0

12-month price target

22,61

Consensus of sell-side coverage.

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

17 analysts · indicative

Ownership→

PNC Investments LLC

largest disclosed fund holder

Profitability→

8,5 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 1099.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 1099.HK. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Sinopharm Group Co Ltd (1099.HK) is a healthcare company operating in the pharmaceuticals and medical research industry. The firm generates revenue through the sale of pharmaceutical products. It is headquartered in China and is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

ActivityPharmaceuticals & Medical Research

AI synthesis

GENERATED

Sinopharm Group Co Ltd has a debt-to-equity ratio of 0.85, indicating a moderate level of leverage, and a current ratio of 1.41, suggesting it has sufficient short-term assets to cover its short-term liabilities. The company's liquidity position is assessed as medium, with a key flag indicating that net cash is negative after subtracting total debt.

The company's profitability is reflected in a return on equity (ROE) of 8.52% and a return on assets (ROA) of 1.83%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, indicating that Sinopharm Group Co Ltd is generating returns, but not at a level that would be considered exceptional.

Sinopharm Group Co Ltd's revenue is primarily derived from its pharmaceutical operations, with no specific segments or geographic regions highlighted in the provided data. The company's revenue concentration is not specified, but the absence of detailed segment data suggests that it may not have a highly diversified revenue base.

The company's growth trajectory is not explicitly detailed in the provided data. However, the capital expenditure of -1.62 billion CNY indicates that the company is not investing heavily in new projects or infrastructure, which may suggest a conservative approach to growth.

The risk assessment for Sinopharm Group Co Ltd indicates a low potential for dilution, with no immediate pressure for share issuance. The company's liquidity risk is moderate, and its credit risk is not explicitly detailed in the provided data.

Recent events and filings for Sinopharm Group Co Ltd are not detailed in the provided data. Analysts have provided a mean price target of 22.61 CNY and a median price target of 22.80 CNY, with a mean recommendation of 2.12, indicating a generally positive outlook from analysts.

Key takeaways

Sinopharm Group Co Ltd has a moderate level of leverage with a debt-to-equity ratio of 0.85.
The company's return on equity is 8.52%, which is below the typical thresholds for strong performance in the pharmaceutical industry.
The company's liquidity position is assessed as medium, with a key flag indicating that net cash is negative after subtracting total debt.
Analysts have provided a generally positive outlook, with a mean price target of 22.61 CNY and a median price target of 22.80 CNY.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

HK$17,43

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

HK$83.95B

Net cashⓘ

-HK$70.96B

Current ratioⓘ

1.4

Debt / equityⓘ

0.8

ROAⓘ

1.8%

ROEⓘ

8.5%

Cash conversionⓘ

198.0%

CapEx / revenueⓘ

-0.3%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

2,49

Predicted surprise

-0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-20 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	2,49
Revenue	—no estimate	—no estimate	594,7B CNY
Operating income	—no estimate	—no estimate	17,8B CNY

Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution17 analysts

Strong buy4

Buy7

Hold6

Sell0

Strong sell0

12-month price targetHK$22,61 · Median HK$22,80

Low HK$17,00High HK$26,97

Operating income · consensus17,8B CNY

EPS surprise

−7,8 %

reported vs consensus · miss

Revenue surprise

−3,3 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

LowHK$17,00

MeanHK$22,61

MedianHK$22,80

HighHK$26,97

SpotHK$17,43

+29.7 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin2,7 %Below median

Net Margin1,2 %Below median

ROE8,5 %Above median

Capex / Rev-0,3 %Above P75

D/E0,85Bottom quartile

Cash Conv1,98Above P75

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

Sinopharm Group Co Ltd Market data — financials · 2026-05-26
Sinopharm Group Co Ltd Market data — analyst estimates · 2026-05-26
Sinopharm Group Co Ltd Market data — ESG · 2026-05-26

Ownership & reference

Top holders

PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

Leadership

Qingming YuExecutive Chairman of the Board

Insider activity

— missing data

Short positioning

— missing data

Index membership

Hang Seng

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

1099.HKCanonical

HKEX · HKD

Intel & risk

PredictorBeat prob45 %Surprise-0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread